NICE appraisal survey

Printer-friendly version

Your views

Entrance to NICE office in LondonThe National Institute for Health and Care Excellence (NICE) will be appraising a treatment called  risankizumab for treating moderate to severe plaque psoriasis in May 2019. The treatment is classed as a systemic biologic agent, given as a self-administered subcutaneous injection. The proposed use of the treatment will probably be at the same point in the psoriasis treatment pathway as other similar treatments, which include: adalimumab, etanercept, ustekinumab, ixekizumab, brodalumab, guslekumab and infiximab.

The pathway for treating psoriasis in order is: Topical therapies (applied to the skin, coricosteroids, vitamin D analogues, coal tar) Phototherapy (PUVA, UVB narrow and broadband) non-biologic systemic therapies (methotrexate, ciclosporin, acitretin) then a systemic biologic agent is offered subject to eligibility, which is classed as failure of previous treatments, contraindication to non-biologic therapies and or severity based on Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores.

PAPAA will be making a written submission of the patients’ perspective for this appraisal. We would like to include your views and opinions within that submission. All responses will be used anonymously; we will use real quotes within our submission.

To take-part complete the form below and submit.

Thank you.


This question is for testing whether you are a human visitor and to prevent automated spam submissions.